There was a notable absence last week when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced in a ...

Chikungunya, a mosquito-borne virus, has been detected at higher-than-expected rates among U.S. travelers from the Indian state. To reduce infection risk, the CDC urges travelers to adopt mosquito ...

A study published in The Lancet Planetary Health reveals that tropical mosquito-borne diseases such as dengue and chikungunya ...

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for chikungunya, a virus transmitted by mosquitoes. The recommendations were approved ...

May 21 (Reuters) - The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for chikungunya ... of the CDC. Sign up here.

Typical symptoms of chikungunya include fever, severe joint pain, headache, muscle pain and a rash, according to the CDC. Most people recover within a week, but some may experience “severe and ...

CINCINNATI (WKRC) — A vaccine designed to protect against chikungunya, a mosquito-borne ... the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA).

"CDC and FDA recently investigated five hospitalisations ... IXCHIQ contains a live, weakened version of the chikungunya virus and may cause symptoms similar to those of chikungunya disease.

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths. About 80,000 Ixchiq doses ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who received the Ixchiq chikungunya vaccine. The FDA and the Centers for Disease ...